1）Watanabe H, Morimoto T, Natsuaki M, et al. Comparison of Clopidogrel Monotherapy After 1 to 2 Months of Dual Antiplatelet Therapy With 12 Months of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome : The STOPDAPT-2 ACS Randomized Clinical Trial. JAMA Cardiol 2022 ; 7 : 407-17.
2）Kim BK, Hong SJ, Cho YH, et al. Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome : The TICO Randomized Clinical Trial. JAMA 2020 ; 323 : 2407-16.
3）Natsuaki M, Morimoto T, Yamamoto E, et al. One-year outcome of a prospective trial stopping dual antiplatelet therapy at 3 months after everolimus-eluting cobalt-chromium stent implantation : ShortT and OPtimal duration of Dual AntiPlatelet Therapy after everolimus-eluting cobalt-chromium stent（STOPDAPT）trial. Cardiovasc Interv Ther 2016 ; 31 : 196-209.
4）Watanabe H, Domei T, Morimoto T, et al. Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI : The STOPDAPT-2 Randomized Clinical Trial. JAMA 2019 ; 321 : 2414-27.
5）Dewilde WJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention : an open-label, randomised, controlled trial. Lancet 2013 ; 381 : 1107-15.
6）Cannon CP, Bhatt DL, Oldgren J, et al. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. N Engl J Med 2017 ; 377 : 1513-24.
7）Gibson CM, Mehran R, Bode C, et al. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. N Engl J Med 2016 ; 375 : 2423-34.
8）Lopes RD, Heizer G, Aronson R, et al. Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. N Engl J Med 2019 ; 380 : 1509-24.
9）Vranckx P, Valgimigli M, Eckardt L, et al. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation（ENTRUST-AF PCI） : a randomised, open-label, phase 3b trial. Lancet 2019 ; 394 : 1335-43.
10）Yasuda S, Kaikita K, Akao M, et al. Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease. N Engl J Med 2019 ; 381 : 1103-13.
11）Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007 ; 357 : 2001-15.
12）Koo BK, Kang J, Park KW, et al. Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention（HOST-EXAM） : an investigator-initiated, prospective, randomised, open-label, multicentre trial. Lancet 2021 ; 397 : 2487-96.
13）Brouwer J, Nijenhuis VJ, Delewi R, et al. Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation. N Engl J Med 2020 ; 383 : 1447-57.
14）Dangas GD, Tijssen JGP, Wöhrle J, et al. A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement. N Engl J Med 2020 ; 382 : 120-9.
15）Collet JP, Van Belle E, Thiele H, et al. Apixaban vs. standard of care after transcatheter aortic valve implantation : the ATLANTIS trial. Eur Heart J 2022 ; 43 : 2783-97.
16）Inohara T, Otsuka T, Watanabe Y, et al. Rationale and design of Non-antithrombotic Therapy After Transcatheter Aortic Valve Implantation（NAPT）Trial. Contemp Clin Trials 2023 ; 134 : 107358.
17）Nijenhuis VJ, Brouwer J, Delewi R, et al. Anticoagulation with or without Clopidogrel after Transcatheter Aortic-Valve Implantation. N Engl J Med 2020 ; 382 : 1696-707.
18）Van Mieghem NM, Unverdorben M, Hengstenberg C, et al. Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR. N Engl J Med 2021 ; 385 : 2150-60.
19）van Ginkel DJ, Bor WL, Aarts HM, et al. Impact of Continuation Versus Interruption of Oral Anticoagulation During TAVI on Health-Related Quality of Life. Catheter Cardiovasc Interv 2025 ; 392 : 438-49.
20）Stone GW, Lindenfeld J, Abraham WT, et al. Transcatheter Mitral-Valve Repair in Patients with Heart Failure. N Engl J Med 2018 ; 379 : 2307-18.
21）Sorajja P, Whisenant B, Hamid N, et al. Transcatheter Repair for Patients with Tricuspid Regurgitation. N Engl J Med 2023 ; 388 : 1833-42.
22）Freeman JV, Higgins AY, Wang Y, et al. Antithrombotic Therapy After Left Atrial Appendage Occlusion in Patients With Atrial Fibrillation. J Am Coll Cardiol 2022 ; 79 : 1785-98.
23）Asami M, Naganuma T, Ohno Y, et al. Initial Japanese Multicenter Experience and Age-Related Outcomes Following Left Atrial Appendage Closure : The OCEAN-LAAC Registry. JACC Asia 2023 ; 3 : 272-84.
24）Carvalho PEP, Gewehr DM, Miyawaki IA, et al. Network Meta-Analysis of Initial Antithrombotic Regimens After Left Atrial Appendage Occlusion. J Am Coll Cardiol 2023 ; 82 : 1765-73.
25）Freixa X, Cruz-González I, Cepas-Guillén P, et al. Low-Dose Direct Oral Anticoagulation vs Dual Antiplatelet Therapy After Left Atrial Appendage Occlusion : The ADALA Randomized Clinical Trial. JAMA Cardiol 2024 ; 9 : 922-6.
26）Guedeney P, Farjat-Pasos JI, Asslo G, et al. Impact of the antiplatelet strategy following patent foramen ovale percutaneous closure. Eur Heart J Cardiovasc Pharmacother 2023 ; 9 : 601-7.
27）Wintzer-Wehekind J, Alperi A, Houde C, et al. Impact of Discontinuation of Antithrombotic Therapy Following Closure of Patent Foramen Ovale in Patients With Cryptogenic Embolism. Am J Cardiol 2019 ; 123 : 1538-45.
